# US 2025/0144231 A1 · Compositions and methods for localized delivery of cytokines for adoptive cell therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144231 A1
- Document ID: US20250144231A1
- Status: Published application
- Kind: A1
- Application number: 18/912,122
- Filed: 2024-10-10
- Published: 2025-05-08
- Earliest claimed: 2022-04-13
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: David J. Mooney; Yutong Liu; Hua Wang
- Web page: https://patentgrep.com/patent/US20250144231A1

## CPC

- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 38/2013: {IL-2}
- A61K 38/208: {IL-12}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61P 35/00: Antineoplastic agents
- C12N 5/0006: {Modification of the membrane of cells, e.g. cell decoration}
- C12N 5/0636: {T lymphocytes}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are compositions and methods for metabolically labeling cells using click chemistry reagents. The compositions and methods disclosed herein provide a specific and efficient means of localizing desired agents, such as anti-tumor cytokines, to a variety of cell types for adoptive cell therapy.

## Claims

### Claim 1

A method of preventing or treating a cancer in a subject, of enhancing an immune response against a cancer in a subject, or of delivering a non-toxic level of cytokine to a subject, comprising administering to the subject an adoptive cell therapy, wherein the adoptive cell therapy comprises:
(i) an immune cell comprising a cell-surface glycoprotein coupled to a first click reagent; and
(ii) a cytokine coupled to a second click reagent,
wherein the cell-surface glycoprotein is covalently linked to the cytokine through a selective reaction between the first click reagent and the second click reagent,
thereby preventing or treating the cancer, enhancing an immune response against the cancer or delivering the non-toxic level of cytokine to the subject.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, further comprising contacting the immune cell with an unnatural sugar and/or an unnatural sugar nanoparticle to produce the immune cell comprising the cell-surface glycoprotein coupled to a first click reagent.

### Claim 5

A method of treating a subject in need thereof with an adoptive cell therapy, comprising:
(i) contacting an immune cell with an unnatural sugar and/or an unnatural sugar nanoparticle to produce an immune cell comprising a cell-surface glycoprotein coupled to a first click reagent; and
(ii) administering to the subject the immune cell comprising the cell-surface glycoprotein coupled to the first click reagent, and a cytokine coupled to a second click reagent,
wherein the cell-surface glycoprotein is covalently linked to the cytokine through a selective reaction between the first click reagent and the second click reagent,
thereby treating a subject in need thereof with an adoptive cell therapy.

### Claim 6 (depends on 1)

The method of claim 1,
(i) wherein the first click reagent is selected from the group consisting of an azide group, a dibenzocyclooctyne (DBCO) group, a transcyclooctene group, a tetrazine group, a norbornene group, and variants thereof, optionally wherein the first click reagent comprises an azide group;
(ii) wherein the second click reagent is selected from the group consisting of an azide group, a dibenzocyclooctyne (DBCO) group, a transcyclooctene group, a tetrazine group, a norbornene group, and variants thereof;
(iii) wherein the second click reagent comprises a dibenzocyclooctyne (DBCO) group; and/or
(iv) wherein the first click reagent comprises an azide group and the second click reagent comprises a dibenzocyclooctyne (DBCO) group.

### Claim 7 (depends on 4)

The method of claim 4, wherein the unnatural sugar and/or an unnatural sugar nanoparticle comprises the first click reagent, optionally wherein the unnatural sugar and/or an unnatural sugar nanoparticle is an unnatural azido-sugar and/or an unnatural azido-sugar nanoparticle.

### Claim at position 8

-10. (canceled)

### Claim 11 (depends on 6)

The method of claim 6, (i) wherein the DBCO group is coupled to a primary amine of the cytokine; and/or (ii) wherein the cytokine is coupled to between 1-10 DBCO groups, optionally wherein the cytokine is coupled to 1, 2, or 3 DBCO groups.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein:
(i) the cytokine is selected from the group consisting of interleukins, interferons, chemokines, tumor necrosis factors, and colony stimulating factors of immune cell precursors;
(ii) the cytokine is an interleukin selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, and IL-35;
(iii) the cytokine is a chemokine selected from the group consisting of CCL family, CXCL family, CX3CL family, and XCL family chemokines.
(iv) the cytokine is an inflammatory cytokine selected from the group consisting of IFN-γ, IL-1, and TNF-α;
(v) the cytokine is selected from the group consisting of interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-10 (IL-10), interleukin-12 (IL-12), interleukin-15 (IL-15), IL-15/IL-15Rα, interleukin-18 (IL-18), interleukin-21 (IL-21), interleukin-27 (IL-27), interferon-α (IFN-α), interferon- (IFN-), granulocyte macrophage-colony stimulating factor (GM-CSF), Fms-like tyrosine kinase receptor 3 ligand (Flt3-L), tumour necrosis factor α (TNF-α), and combinations thereof;
(vi) the cytokine is an anti-tumor cytokine;
(vii) the cytokine is IL-2; and/or
(viii) the cytokine is administered to the subject prior to, concurrently with, or after the administration of the immune cell.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the selective reaction between the first click reagent and the second click reagent occurs in vitro, ex vivo, or in vivo.

### Claim 17 (depends on 1)

The method of claim 1,
(i) wherein the immune cell comprises a lymphocyte, optionally a tumor-infiltrating lymphocyte;
(ii) wherein the immune cell comprises a T-cell, a B-cell, a natural killer (NK) cell, a regulatory T (Treg) cell, or a combination thereof; or
(iii) wherein the immune cell comprises an engineered T cell receptor (TCR) and/or a chimeric antigen receptor (CAR).

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the adoptive cell therapy is selected from the group consisting of
(i) a tumor-infiltrating lymphocyte (TIL) therapy;
(ii) a engineered T cell receptor (TCR) therapy;
(iii) a chimeric antigen receptor (CAR) T cell therapy;
(iv) a natural killer (NK) cell therapy; and
(v) a regulatory T (Treg) cell therapy.

### Claim 21 (depends on 1)

The method of claim 1, which reduces tumor size, delays tumor growth, reduces cancer burden, increases survival time, prevents cancer from developing, depletes cancer cells, prevents or reduces cancer relapse, or prevents or reduces cancer recurrence or metastasis, increases T cells infiltration in solid tumors, increases antigen presentation, and/or increases antigen spreading in the subject; and/or
which results in the targeted delivery of non-toxic levels of one or more cytokines to the subject and/or which reduces cytokine-related toxicity and inhibition on immune cell proliferation as compared with systemic cytokine administration.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein the subject is suffering from a cancer, a viral disease, and/or an autoimmune disease.

### Claim 24 (depends on 23)

The method of claim 23, wherein the cancer is selected from the group consisting of a cancer of the digestive system; a hepatic carcinoma; a liver cancer; a colon cancer; an esophageal cancer; a gastric cancer; a hepatoma; a kidney or renal cancer; an oral cavity cancer; a pancreatic cancer; a prostate cancer; a rectal cancer; a stomach cancer; a basal cell carcinoma; a biliary tract cancer; a lung cancer; a bladder cancer; a cervical cancer; an endometrial cancer; a uterine cancer; a blond cancer; a bone cancer; a skin cancer; a cancer of the urinary system; and combinations thereof, optionally wherein the cancer is selected from the group consisting of a solid tumor, a leukemia, a lymphoma, and a multiple myeloma, optionally wherein the cancer comprises a solid tumor.

### Claim 25 (depends on 1)

The method of claim 1, wherein the immune cell is administered to the subject prior to, concurrently with, or after the administration of a scaffold, optionally wherein the scaffold comprises an additional agent selected from the group consisting of a growth factor, a differentiation factor, a homing factor, a cytokine, a chemokine, and combinations thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the selective reaction between the first click reagent and the second click reagent occurs in vitro, ex vivo, or in vivo within a scaffold.

### Claim 27

A method of producing an adoptive cell therapy, comprising:
(i) providing an immune cell comprising a cell-surface glycoprotein;
(ii) contacting the immune cell with an unnatural azido-sugar and/or an unnatural azido-sugar nanoparticle to metabolically label the cell-surface glycoprotein with a first click reagent; and
(iii) contacting the immune cell with a cytokine coupled to a second click reagent,
wherein the cell-surface glycoprotein is covalently linked to the cytokine through a selective reaction between the first click reagent and the second click reagent,
thereby producing the adoptive cell therapy.

### Claim 28 (depends on 27)

The method of claim 27, wherein the unnatural azido-sugar nanoparticle comprises a polymer of azido sugar;
optionally, wherein the polymer of azido sugar comprises a tetraacetyl-N-azidoacetylmannosamine (Ac4ManAz) or a derivative thereof;
optionally, wherein the Ac4ManAz is functionalized with at least one acrylate bond;
optionally, wherein the polymer of azido sugar is produced by reversible addition-fragmentation chain-transfer (RAFT) polymerization of Ac4ManAz to yield poly(azido-sugar)n, wherein n is any integer between 1 and 500 (n=1 (G1) or n=500 (G500));
optionally, wherein the unnatural azido-sugar nanoparticle comprises a G400 nanoparticle.

### Claim at position 27

29-32. (canceled)

### Claim 33

An immune cell comprising:
(i) a cell-surface glycoprotein coupled to a first click reagent; and
(ii) a cytokine coupled to a second click reagent;
wherein the cell-surface glycoprotein is covalently linked to the cytokine through a selective reaction between the first click reagent and the second click reagent.

### Claim 34 (depends on 33)

The cell of claim 33,
(i) wherein the immune cell comprises a lymphocyte, optionally a tumor-infiltrating lymphocyte;
(ii) wherein the immune cell comprises a T-cell, a B-cell, a natural killer (NK) cell, a regulatory T (Treg) cell, or a combination thereof; or
(iii) wherein the immune cell comprises an engineered T cell receptor (TCR) and/or a chimeric antigen receptor (CAR).

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37 (depends on 33)

A composition comprising the immune cell of claim 33.
